Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

NKTX.US Logo

NKTX.US - Current Price

$2.18

Company Information

▼
Company Name
Nkarta Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US65487U1088
CIK: 0001787400
CUSIP: 65487U108
Currency: USD
Full Time Employees: 105
Phone: 925 407 1049
Website: https://www.nkartatx.com
Fiscal Year End: December
IPO Date: Jul 10, 2020
Description:

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Address:

1150 Veterans Boulevard, South San Francisco, CA, United States, 94080

Directors & Officers

▼
Name Title Year Born
Mr. Paul J. Hastings CEO & Director 1960
Dr. Nadir Mahmood Ph.D. President and Principal Accounting & Financial Officer 1979
Dr. Shawn Rose M.D., Ph.D. Chief Medical Officer and Head of Research & Development NA

Shares Statistics

▼
Shares Outstanding: 71.03M
Shares Float: 56.36M
% Insiders: 44.50%
% Institutions: 8,549.20%
Short % Float: 11.23%

Valuation Metrics

▼
Enterprise Value: $-50.85M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $154.84M
EBITDA: $-106.94M
Book Value: $4.76
Earnings/Share: $-1.38
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -15.14%
ROE (TTM): -26.69%
Revenue (TTM): $385.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Sep 30, 2025 -0.29 -0.34 N/A 1,420.12%
Jun 30, 2025 -0.31 -0.35 N/A 1,142.86%
Mar 31, 2025 -0.43 -0.45 N/A 444.44%
Dec 31, 2024 -0.35 -0.40 N/A 1,250.00%
Sep 30, 2024 -0.39 -0.36 N/A -833.33%
Jun 30, 2024 -0.34 -0.45 N/A 2,444.44%
Mar 31, 2024 -0.58 -0.56 N/A -357.14%
Dec 31, 2023 -0.57 -0.59 N/A 338.98%
Sep 30, 2023 -0.52 -0.67 N/A 2,238.81%
Jun 30, 2023 -0.60 -0.68 N/A 1,176.47%
Mar 31, 2023 -0.63 -0.70 N/A 1,000.00%
Dec 31, 2022 -0.67 -0.64 N/A -468.75%
Sep 30, 2022 -0.58 -0.62 N/A 645.16%
Jun 30, 2022 -0.61 -0.59 N/A -338.98%
Mar 31, 2022 -0.79 -0.72 N/A -972.22%
Dec 31, 2021 -0.69 -0.90 N/A 2,333.33%
Sep 30, 2021 -0.68 -0.66 N/A -303.03%
Jun 30, 2021 -0.66 -0.62 N/A -645.16%
Mar 31, 2021 -0.59 -0.53 N/A -1,132.08%
Dec 31, 2020 -0.55 -0.44 N/A -2,500.00%
Sep 30, 2020 -0.44 -0.38 N/A -1,578.95%
Jun 30, 2020 -6.08 -6.71 N/A 938.90%
Mar 31, 2020 -0.69 0.00 N/A N/A

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $27.87M $N/A $501.20M $93.23M $407.98M
2023-12-31 $31.04M $N/A $378.89M $105.60M $273.29M
2022-12-31 $37.49M $N/A $472.94M $100.73M $372.21M
2021-12-31 $60.82M $N/A $273.90M $22.94M $250.97M
2020-12-31 $96.69M $N/A $337.65M $16.43M $321.22M
2019-12-31 $20.61M $N/A $48.41M $73.89M $-25.48M
2018-12-31 $7.87M $N/A $9.61M $15.00M $-5.40M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 15, 2025 N/A N/A N/A N/A N/A N/A
Jan 15, 2025 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist